Tech Company Financing Transactions
BioAtla Funding Round
BioAtla closed a $45 million funding round on 1/11/2016. Investors included Global BIO Impact Fund.
Transaction Overview
Company Name
Announced On
1/11/2016
Transaction Type
Debt
Venture Equity
Venture Equity
Amount
$45,000,000
Round
Undisclosed
Investors
Global BIO Impact Fund (John Evey)
Proceeds Purpose
Through the program funding, Global BIO will share in the risks and the potential returns of BioAtla's first four CAB candidates that receive Investigational New Drug (IND) approval by the U.S. Food and Drug Administration.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
11085 Torreyana Rd.
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Website
Email Address
Overview
BioAtla (Nasdaq: BCAB) is a San Diego biotech company that develops novel monoclonal antibody and cell based therapeutics using our proprietary Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO) platforms.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jay Short
Chief Financial Officer
Richard Waldron
Chief Scientific Officer
Gerhard Frey
Co-Founder
Carolyn Short
Vice President
William Boyle
Vice President
Philippe Martin
Vice President
Monica Sullivan
VP - Bus. Development
Michael Melnick
VP - Human Resources
Susie Melody
VP - R & D
Cathy Chang
Browse more venture capital transactions:
Prev: 1/11/2016: Kymeta venture capital transaction
Next: 1/11/2016: Next Step Living venture capital transaction
Share this article
News on VC Transactions
Our team works diligently to report on tech company VC transactions. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs